Pancreatic Cancer Research

ResearcherUniversity of MinnesotaActive in the last 2 years

Adam L. Burrack

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4001-7849; OpenAlex author ID A5014230505; NIH RePORTER profile ID 12482112. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
1
Labs led
1
Collaborators
13
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 2 papers, 1 grant

Papers 11

  1. Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Co-author DOI 10.1126/sciimmunol.adz4302↗
  2. Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2-deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2026-015489↗
  3. IL-15 complex enhances therapeutic efficacy of anti-PD-L1 in a T cell-dependent and NK cell-independent manner in a murine model of pancreatic ductal adenocarc… Co-author DOI 10.1093/jimmun/vkaf314↗
  4. IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-24-0758↗
  5. Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate. Co-author DOI 10.1007/s00262-022-03338-7↗
  6. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.celrep.2023.112732↗
  7. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003525↗
  8. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer. Co-author DOI 10.1172/jci.insight.151593↗
  9. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model. Co-author DOI 10.4049/jimmunol.2000765↗
  10. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.celrep.2019.07.059↗
  11. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/2326-6066.cir-18-0448↗

Grants 1

  1. Elucidating and overcoming T cell dysfunction in pancreatic cancer R50CA293827↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ingunn M. Stromnes · 11 shared papers, 2019–2026 · strength 1.89
  2. Zoe C. Schmiechen · 7 shared papers, 2021–2026 · strength 1.36
  3. Alexander K. Tsai · 4 shared papers, 2025–2026 · strength 0.92
  4. Grant H. Hickok · 4 shared papers, 2023–2026 · strength 0.80
  5. Philip D. Greenberg · 3 shared papers, 2019–2026 · strength 0.47
  6. Sunil R. Hingorani · 3 shared papers, 2019–2026 · strength 0.47
  7. Cara-lin Lonetree · 2 shared papers, 2025–2026 · strength 0.41
  8. Michael T. Patterson · 2 shared papers, 2022–2023 · strength 0.30
  9. David Masopust · 1 shared paper, 2026 · strength 0.23
  10. Paolo Provenzano · 1 shared paper, 2026 · strength 0.23
  11. Guhan Qian · 1 shared paper, 2026 · strength 0.23
  12. Liang‐I Kang · 1 shared paper, 2026 · strength 0.22
  13. David G DeNardo · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.